$AKTX shares were up, gaining 28 percent to $7.54 after surging 224.18 percent on Wednesday. The company announced a successful Type B, pre-IND meeting with the FDA regarding Akari's proposed pivotal clinical trial program for hematopoietic stem cell transplant-related thrombotic microangiopathy.